A5057554188- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- HIV/AIDS drug development and treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Melanoma and MAPK Pathways
- Synthesis and biological activity
- Click Chemistry and Applications
Massachusetts General Hospital
2020-2025
Harvard University
2022-2023
IDH2 (isocitrate dehydrogenase 2) mutations occur in approximately 15% of patients with acute myeloid leukemia (AML). The inhibitor enasidenib was recently approved for IDH2-mutated relapsed or refractory AML. We conducted a multi-center, phase I trial maintenance following allogeneic hematopoietic cell transplantation (HCT) malignancies. Two dose levels, 50mg and 100mg daily were studied 3 × dose-escalation design, 10 additional treated at the recommended 2 (RP2D). Enasidenib initiated...
Abstract Purpose: Isocitrate dehydrogenase 1 (IDH1) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use IDH1-mutated AML. Patients and Methods: We conducted a multicenter, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up 12 28-day cycles. The first dose level 500 mg daily, reduction 250 if needed, 3 × de-escalation...
<div>Abstract<p>Purpose: <i>IDH1</i> (isocitrate dehydrogenase 1) mutations occur in 5-10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use <i>IDH1</i>-mutated AML. Patients and Methods: We conducted a multi-center, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up to twelve 28-day cycles. The first dose level...
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Representativeness of Study Participants</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<p>Representativeness of Study Participants</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
9511 Background: Standard MAPK-targeted therapy (tx) for pts with BRAF MT MM involves combined and MEK inhibition high efficacy in advanced melanoma, but durability of response is limited by acquired resistance. One combination, dabrafenib trametinib (DT), was shown to be less effective the frontline setting than immune checkpoint (ICI) did achieve a 48% objective rate (ORR) after ICI. (Atkins et al., JCO 2022) Preclinical data show that targeting mediators apoptosis improves survival...
<p>Representativeness of Study Participants</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Marrow IDH1 VAF prior to Transplant and Maintenance</p>
<p>Representativeness of Study Participants</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<p>Supplemental Figure 2: Overall and progression-free survival for patients according to NPM1 mutational status</p>
<div>Abstract<p>Purpose: <i>IDH1</i> (isocitrate dehydrogenase 1) mutations occur in 5-10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use <i>IDH1</i>-mutated AML. Patients and Methods: We conducted a multi-center, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) was initiated between days 30 90 HCT continued up to twelve 28-day cycles. The first dose level...
<div>AbstractPurpose:<p>Isocitrate dehydrogenase 1 (<i>IDH1</i>) mutations occur in 5% to 10% of patients with acute myeloid leukemia (AML). Ivosidenib is an IDH1 inhibitor, approved for use <i>IDH1</i>-mutated AML.</p>Methods:<p>We conducted a multicenter, phase I trial maintenance ivosidenib following allogeneic hematopoietic cell transplantation (HCT) AML. was initiated between days 30 and 90 HCT continued up 12 28-day cycles. The first dose...
<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second treatment.</p>